XML 50 R41.htm IDEA: XBRL DOCUMENT v3.25.3
Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized $ 1,076 $ 123 $ 5,163 $ 26,486
AstraZeneca Agreements [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized 165,300 42,200 218,600 115,300
Drug Product Revenue, Net [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized 957 (262) 4,767 24,954
Drug Product Revenue, Net [Member] | Astellas Agreement [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized 1,000 (300) 4,800 (700)
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Japan [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized (378) (1,355) 1,446 (3,926)
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Europe [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized 1,335 1,093 3,321 3,209
Drug Product Revenue, Net [Member] | AstraZeneca Agreements [Member] | U.S. [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized $ 0 $ 0 $ 0 $ 25,671